Remove Biosimilars Remove Generic Medicine Remove Vaccines
article thumbnail

EMA human medicines committee (CHMP) highlights, November 2022

European Pharmaceutical Review

Four medicines recommended for approval in the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP)’s latest meeting included a biosimilar for osteoporosis and a novel COVID-19 vaccine. COVID-19 update. 5 in children five to 11 years. CHMP’s safety update.

article thumbnail

Waters, as a strategic partner to the pharma industry, can help India become a world leader in biosimilars

Express Pharma

Many millions of people are vaccinated against COVID-19, thanks to a messenger RNA (mRNA) encapsulated within a lipid nanoparticle. For decades, Waters has been a trusted partner to many pharma and generics companies operating in India, particularly for small molecule QA/QC. How poised are you to leverage them?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CHMP meeting highlights – June 2024

European Pharmaceutical Review

the CHMP gave a positive opinion for the first nasally administered emergency treatment for allergic reactions” A positive opinion was granted to the mResvia (Respiratory Syncytial Virus (RSV) mRNA vaccine). The committee gave a positive opinion for the biosimilar Steqeyma (ustekinumab). 1 virus variant.

article thumbnail

EMA human medicines committee (CHMP) highlights, September 2022

European Pharmaceutical Review

Biosimilar medicine Ximluci (ranibizumab) for the treatment of neovascular age-related macular degeneration, a progressive retinal macular disease, causing gradual vision impairment, mainly in the elderly population. Adapted vaccines Comirnaty Original/Omicron BA.1 Adapted vaccines Comirnaty Original/Omicron BA.1

article thumbnail

CHMP meeting highlights – March 2023

European Pharmaceutical Review

It is the eighth vaccine recommended in the European Union (EU) for COVID-19. The CHMP adopted a positive opinion for Epysqli (eculizumab), a biosimilar medicine for paroxysmal nocturnal haemoglobinuria. The committee adopted a positive opinion for Briumvi (ublituximab) for relapsing multiple sclerosis (MS).

article thumbnail

CHMP meeting highlights: February 2024

European Pharmaceutical Review

At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines.

article thumbnail

Standards support medicines supply chain resilience and the future of quality

Quality Matters

Launched in 2021 and composed of more than 250 million data points spanning 92% of generic medicines approved in the U.S., Perhaps most noticeably during the COVID-19 pandemic, this included approval or authorization of an unprecedented number of novel vaccines that help save lives.